Medical management of COVID-19: treatment options under consideration
DOI:
https://doi.org/10.18203/2349-3933.ijam20203997Keywords:
COVID-19, Hydroxychloroquine, Remdesivir, SARS-CoV-2Abstract
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. Despite the worsening trends of COVID-19, currently, no drugs are validated to have significant efficacy in the clinical treatment of COVID-19. The drugs currently being explored are hydroxychloroquine, antivirals like remdesivir, favipiravir alone or in combination, antibiotics like azithromycin and doxycycline. Low dose corticosteroids, either oral or intravenous, have also shown promising results in reducing mortality. On the other hand, Immunomodulators and biologics are found to be very effective in some cases. Autopsy finding of patients with COVID-19 shows the evidence of endothelial damage and formation of microthrombi with multiorgan involvement and, ultimately, multiorgan failure; hence anticoagulants also seem to have a definite role in preventing microvasculature clogging and multiorgan dysfunction. Pulmonary vasodilators acting via the cGMP/cAMP pathway may also prove to be beneficial in reducing airway hyper inflammation. In this review, authors have attempted to summate the potential drugs therapies with emphasis on convalescent plasma, and at last, the most awaited thing of this pandemic, COVID-19 vaccine.
References
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71(15):732-9.
Wang M, Cao R, Zhang L,Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020;75(7):1667-70.
Xing Li, Ying Wang, Agostinis P, Rabson A, Melino G, Carafoli E et al. Is hydroxychloroquine beneficial for COVID-19 patients? Cell Death Dis. 2020;11(7):512.
Risch HA. Early outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that should be Ramped-up immediately as Key to the Pandemic Crisis. Am J Epidemiol. 2020;kwaa152.
Furata Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-63.
Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153;85-94.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicenter trial. Lancet 2020;6;395(10236):1569-78.
NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19. Available from-https://www.nih.gov/news-events/news-releases/nih-clinical-trialshows-remdesivir-accelerates-recovery-advanced-covid-19. Accessed on 29 April 2020.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A et al. Compassionate use of Remdesivir for patients with severe Covid-19. N Engl J Med 2020;382(24):2327-36.
B Cao, Y Wamg, D Wen, Liu W, Wang J, Fan G et al. A trial of Lopinavir-Ritonavir in adults Hospitalized with Severe COVID-19. N Engl J Med. 2020;282:1787-99.
Osborne V, Davie M, Lane S, Evans A, Denyer J, Dhanda S et al. Lopinavir-Ritonavir in the treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Drug Safety. 2020 Aug;43(8):809-21.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506.
Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W et al. Clinical efficacy of Arbidol in patients with 2019 novel coronavirus-infected pneumonia: A retrospective cohort study. J Infect Public Health. 2020;13(9):1187-95.
Li Y, Xie Z. Efficacy and safety of Lopinavir/ritonavir or Arbidol in adult patients with mild/moderate COVID-19: An exploratory randomized controlled trial. Med. 2020.
Tay MY, Fraser JE, Chan WK. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Res. 2013;99(3):301-6.
Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851-6.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020:104787.
The FDA’s Center for Veterinary Medicine, https://www.fda. Gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment. Accessed on 29 April 2020.
Fu B, Xu X and Wei H. Why tocilizumab could be an effective treatment for severe COVID- 19. J Transl Med. 2020;18(1):164.
H.A. Schlosser, M. Schlaak, Malarkannan S. Cytokine release syndrome, J Immunother Cancer. 2018;6:56
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62.
S. Begum-Haque, A. Sharma, I.R. Kasper. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis J. Neuroimmunol. 2008;204:58-65
Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D et al. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020;S0163-4453(20)30228-0.
Elisabeth Mahase. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ. 2020;369:m2422.
Raymond M Johnson, Joseph M Vinetz. Dexamethasone in the management of COVID-19. BMJ. 2020;370:m2648.
Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7:ofaa102.
Juan Simon Rico-Mesa, Daniel Rosas, Ashkan Ahmadian-Tehrani et al. The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. Current Cardiology Reports. 2020;22:53.
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Thromb Haemost. 2020.18(6):1421-4.
Jean M. Connors1 and Jerrold H. Levy2-4 COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-40.
Hung IF, Lung KC, Tso EY, Liu R, Hin Chung TW, Chu MY et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomized, phase 2 trial. Lancet. 2020;395(10238):1695-704.
Uematsu S, Akira S. Toll-like receptors and Type I interferons. J Biol Chem. 2007; 282(21):15319-23.
Chan JF, Yao Y, Yeung ML, et al. Treatment with Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015;212(12):1904-13.
Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020;11:1061.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56(1):105949.
Isidori AM, Giannetta E, Pofi R, Venneri MA, Gianfrilli D, Campolo F et al. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. Andrology. 2020;1.
Bridgewood C, Damiani G, Sharif K, Watad A, Bragazzi NL, Quartuccio Let al. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond. Isr Med Assoc J. 2020;22(6):335-9.
Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020; 92:479-90
Qayyumi B, Sharin F, Singh A. Management of COVID-19: A brief overview of the various treatment strategies. Cancer Res Stat Treat. 2020;3:233-43.
Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW et al. review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. 2020;40(5):416-37.
Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ. 2020; 368:m1256.
India Today. Coronavirus: India in final stages of framing protocols for clinical trial of plasma therapy, says ICMR. Available from: https://www. indiatoday.in/science/story/coronavirus-india-kerala-finalstages- framing-protocols-for-clinical-trial-of-plasma-therapy. icmr-1665509-2020-04-10. Accessed on 10 April 2020.
Editorial. Race for a COVID-19 vaccine. E Bio Medicine. 2020;55:102817.
Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20:375-88.
Gupta P, Mohanty A, Narula H, Singh V, Kalita D, Varshney S et al. Concise Information for the Frontline Health care workers in the era of COVID-19- A Review. Indian J Comm Health. 2020;32(2):215-24.
Mohanty A, Kabi A, Mohanty AP, Kumar N, Kumar S. Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges: An Indian Perspective. J Adv Med Medic Rese. 2020;32(14):10-7.
Mohanty A, Kabi A, Mohanty AP. Health problems in healthcare workers: A review. J Family Med Prim Care. 2019;8(8):2568-72.
